Company intelligence / Profile preview

The Grit City

Shenzhen, Guangdong（assumed from Shenzhen HQ）, 中国（China）thegritcity.com ↗

Ownership: Private
Development stage: Commercial

Overview

GT101 has reached pivotal Phase II study status as the first TIL product to do so in China, with plans to file BLA by end of next year; GT201 represents a next-generation gene-edited TIL approach now cleared for human studies by both US FDA & Chinese regulators.

Therapeutic areas: Oncology
Modalities: Cell therapyGene-edited cell therapy
Industry: Biotech

Partnerships

Not explicitly listed; company is backed by renowned venture capital funds

Beyond the preview

Go deeper on The Grit City.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on The Grit City.

Explore the full profile